NO20053775L - Diazepinoindol derivater som kinaseinhibitorer. - Google Patents

Diazepinoindol derivater som kinaseinhibitorer.

Info

Publication number
NO20053775L
NO20053775L NO20053775A NO20053775A NO20053775L NO 20053775 L NO20053775 L NO 20053775L NO 20053775 A NO20053775 A NO 20053775A NO 20053775 A NO20053775 A NO 20053775A NO 20053775 L NO20053775 L NO 20053775L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
diazepinoindole
derivatives
compounds
diazepinoindole derivatives
Prior art date
Application number
NO20053775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053775D0 (no
Inventor
Min Teng
Sacha Ninkovic
Michael John Bennett
Yuanjin Eugene Rui
Fen Wang
Suzanne Pritchett Benedict
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20053775D0 publication Critical patent/NO20053775D0/no
Publication of NO20053775L publication Critical patent/NO20053775L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20053775A 2003-01-09 2005-08-08 Diazepinoindol derivater som kinaseinhibitorer. NO20053775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20053775D0 NO20053775D0 (no) 2005-08-08
NO20053775L true NO20053775L (no) 2005-09-16

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053775A NO20053775L (no) 2003-01-09 2005-08-08 Diazepinoindol derivater som kinaseinhibitorer.

Country Status (35)

Country Link
US (3) US6967198B2 (el)
EP (2) EP1585749B1 (el)
JP (1) JP3990718B2 (el)
KR (1) KR100697746B1 (el)
CN (1) CN1759118B (el)
AP (1) AP2048A (el)
AT (1) ATE404564T1 (el)
AU (1) AU2004203977B2 (el)
BR (1) BRPI0406701A (el)
CA (1) CA2512683C (el)
CR (1) CR7899A (el)
CY (1) CY1108408T1 (el)
DE (1) DE602004015724D1 (el)
DK (1) DK1585749T3 (el)
EA (1) EA009337B1 (el)
EC (1) ECSP055911A (el)
ES (1) ES2309484T3 (el)
GE (1) GEP20084367B (el)
HK (1) HK1086257A1 (el)
HR (1) HRP20050624A2 (el)
IL (1) IL169082A (el)
IS (1) IS7884A (el)
MA (1) MA27703A1 (el)
MX (1) MXPA05007352A (el)
NO (1) NO20053775L (el)
NZ (1) NZ540638A (el)
OA (1) OA13017A (el)
PL (1) PL378372A1 (el)
PT (1) PT1585749E (el)
RS (1) RS20050522A (el)
SI (1) SI1585749T1 (el)
TN (1) TNSN05176A1 (el)
UA (1) UA80733C2 (el)
WO (1) WO2004063198A1 (el)
ZA (1) ZA200504674B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
AU2004203977B2 (en) * 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
AU2006215413B2 (en) * 2005-02-18 2010-10-07 Astrazeneca Ab Method for determining responsiveness to CHK1 inhibitors
UA92164C2 (ru) 2005-03-29 2010-10-11 Айкос Корпорейшен Соединения, пригодные для угнетения снк1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
NZ565378A (en) 2005-06-29 2011-03-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
AU2006279541A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
US8143052B2 (en) 2005-08-25 2012-03-27 Ube Industries, Ltd. Process for preparing optically active (S or R)-α amino acid and (R or S)-α amino acid ester in one phase organic reaction medium
WO2007025303A2 (en) * 2005-08-26 2007-03-01 The Regents Of The University Of California Non-steroidal antiandrogens
EP2004655A1 (en) * 2006-04-04 2008-12-24 Pfizer Products Incorporated Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
RU2409361C2 (ru) * 2006-04-04 2011-01-20 Пфайзер Продактс Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
EP2705036B1 (en) 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
KR101684039B1 (ko) 2011-12-31 2016-12-07 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
SG11201401726VA (en) 2011-12-31 2014-10-30 Beigene Ltd Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為parp抑制劑的稠合四或五環二氫二氮呯并咔唑酮
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法
AU2016312011B2 (en) * 2015-08-25 2021-02-04 Beigene, Ltd. Process for preparing Parp inhibitor, crystalline forms, and uses thereof
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
TW201840564A (zh) 2017-02-28 2018-11-16 英屬開曼群島商百濟神州有限公司 稠合的四環或五環二氫二氮呯幷哢唑酮的鹽的結晶形式及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
CN111108105B (zh) * 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3914284A4 (en) * 2019-01-25 2022-10-26 Numedii, Inc. METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
JP7260718B2 (ja) 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのChk1阻害剤としての使用
CA3184988A1 (en) * 2020-07-13 2022-01-20 Ahmed Mamai Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
CN115698019A (zh) * 2020-07-31 2023-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
WO2000016781A1 (en) 1998-09-18 2000-03-30 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
WO2001016306A2 (en) 1999-08-27 2001-03-08 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
US6881575B1 (en) 1999-09-22 2005-04-19 Canbas Co., Ltd. Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
MXPA03004832A (es) * 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
AU2004203977B2 (en) * 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
CA2512683A1 (en) 2004-07-29
TNSN05176A1 (fr) 2007-06-11
PL378372A1 (pl) 2006-04-03
NO20053775D0 (no) 2005-08-08
UA80733C2 (en) 2007-10-25
IL169082A (en) 2011-02-28
EA009337B1 (ru) 2007-12-28
NZ540638A (en) 2007-12-21
SI1585749T1 (sl) 2008-10-31
HK1086257A1 (en) 2006-09-15
JP2006516274A (ja) 2006-06-29
US20050075499A1 (en) 2005-04-07
OA13017A (en) 2006-11-10
EP1585749A1 (en) 2005-10-19
RS20050522A (en) 2007-12-31
MA27703A1 (fr) 2006-01-02
CN1759118B (zh) 2010-12-08
AP2005003353A0 (en) 2005-09-30
ATE404564T1 (de) 2008-08-15
ES2309484T3 (es) 2008-12-16
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (en) 2008-08-13
DE602004015724D1 (de) 2008-09-25
US7462713B2 (en) 2008-12-09
PT1585749E (pt) 2008-10-23
AP2048A (en) 2009-09-24
KR20050092397A (ko) 2005-09-21
CR7899A (es) 2005-08-05
US7132533B2 (en) 2006-11-07
JP3990718B2 (ja) 2007-10-17
WO2004063198A1 (en) 2004-07-29
ECSP055911A (es) 2005-11-22
US20060004052A1 (en) 2006-01-05
KR100697746B1 (ko) 2007-03-22
ZA200504674B (en) 2006-07-26
HRP20050624A2 (en) 2006-02-28
US20070135415A1 (en) 2007-06-14
EA200500893A1 (ru) 2006-02-24
GEP20084367B (en) 2008-05-13
IS7884A (is) 2005-06-09
US6967198B2 (en) 2005-11-22
AU2004203977B2 (en) 2010-06-17
EP1947102A1 (en) 2008-07-23
CN1759118A (zh) 2006-04-12
MXPA05007352A (es) 2006-02-17
DK1585749T3 (da) 2008-09-22
BRPI0406701A (pt) 2005-12-20
CA2512683C (en) 2010-03-16
CY1108408T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
NO20061746L (no) Kinazolinderivater som antiproliferative midler
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
NO20061743L (no) Kinazolinderivater
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa